/
Oncology
Advanced Cancers
31
Pipeline Programs↗
24
Active Trials↗
46
Companies Involved↗
Advanced Cancers is a moderately active landscape with 31 programs across 46 companies. The most active players are Merck & Co., BiOneCure Therapeutics Inc., CAS Lamvac Biotech Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 19
Phase 222
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
24 of 30 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 100% of 31 pipeline programs.
Analysis
Trial Status
99
clinical trials
Completed48 · 48%
Terminated14 · 14%
Recruiting13 · 13%
Active, not recruiting9 · 9%
Unknown status6 · 6%
Withdrawn5 · 5%
Other4 · 4%
Clinical Trials
Trial Activity
99 trials
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT06188624·150 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)